Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA
- 50 Downloads
Gastrointestinal stromal tumors (GISTs) are the most common soft tissue tumors of the GI tract. Studies have been published reporting additional neoplasms in GIST patients. This study aimed to evaluate possible associations of mutation type, morphology, and clinical aspects of GISTs.
All cases of GIST were identified from our pathology files. Coding exons of KIT and PDGFRA in GISTs with additional malignancies were sequenced.
A total of 70 of 188 (37%) retrieved patients with confirmed diagnosis of GIST showed at least one additional malignant neoplasm. Fifty of these GISTs were located in the stomach (71%), 8 in the small intestine (11%), 5 in the colon/rectum (7%), and 7 cases (6.2%) were of undetermined sites of origin. The distribution of identified mutations was similar to that described in GISTs without secondary malignancies. A total of 37 of 57 cases (65%) showed mutations in the KIT gene exon 11, 3 (5%) cases in exon 9, and 1 (2%) case in exon 13. Nine tumors (16%) had mutations of the PDGFRA gene. KIT and PDGFRA wild-type status were found in seven cases (12%). Most of the secondary neoplasms were located within the GI tract (34%), in the urogenital system (24%), or the breast/female genital tract (20%).
This study confirms the high rate of additional malignant tumors in GIST patients. GIST features in these cases are very similar to those with sole GIST.
KeywordsGastrointestinal stromal tumor GIST Mutation Additional/secondary malignancy KIT PDGFRA
We would like to thank Mrs. Monika Müller and Mr. Kai Hebick, both at clinical center Augsburg, for the acquisition of paraffin-embedded tissue and data management as well as Mrs. Ingrid Mons, Department of Pathology of the University of Erlangen, for the support in molecular analysis.
Patrick Mayr: study design, data acquisition and interpretation, manuscript drafting. Bruno Märkl: manuscript drafting and study design.Abbas Agaimy: manuscript drafting and data interpretation. Bernadette Kriening: data acquisition. Sebastian Dintner: data analysis and data acquisition. Gerhard Schenkirsch: data acquisition. Regine Schneider-Stock: study design, data acquisition and interpretation, and manuscript drafting.
This study was financially supported by Novartis AG. There was no influence on the study design, aim, or data analysis.
Compliance with ethical standards
This study was approved by the ethical board of Klinikum Augsburg.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M (2012) A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol 23:1335–1340CrossRefPubMedGoogle Scholar
- 6.Fernández JA, Olivares V, Gómez-Ruiz AJ et al (2018) Additional malignancies in patients with gastrointestinal stromal tumors (GIST): incidence, pathology and prognosis according to a time of occurrence-based classification. Clin Transl Oncol. https://doi.org/10.1007/s12094-018-1966-5
- 10.Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P (2014) Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 120:2325–2333CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769–1776CrossRefPubMedGoogle Scholar
- 19.Rodriquenz MG, Rossi S, Ricci R, Martini M, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D’Argento E, Strippoli A, Barone C, Cassano A (2016) Gastrointestinal stromal tumors (GISTs) and second malignancies: a novel “sentinel tumor”? A monoinstitutional, STROBE-compliant observational analysis. Medicine (Baltimore) 95:e4718CrossRefGoogle Scholar